Long-term outcome and patterns of failure in patients with advanced head and neck cancer

被引:48
作者
Hauswald, Henrik [1 ]
Simon, Christian [2 ]
Hecht, Simone [1 ]
Debus, Juergen [1 ]
Lindel, Katja [1 ]
机构
[1] Heidelberg Univ, Dept Radiat Oncol, Heidelberg, Germany
[2] Heidelberg Univ, Dept Otorhinolaryngol, D-6900 Heidelberg, Germany
关键词
HNSCC; head and neck cancer; radiotherapy; radiochemotherapy; irradiation; long-term follow-up; SQUAMOUS-CELL CARCINOMA; PLUS CONCURRENT CISPLATIN; PHASE-II TRIAL; DISTANT METASTASES; ACCELERATED RADIOTHERAPY; PULMONARY METASTASES; CHEMOTHERAPY; ONCOLOGY; CHEMORADIOTHERAPY; OROPHARYNX;
D O I
10.1186/1748-717X-6-70
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To access the long-time outcome and patterns of failure in patients with advanced head and neck squamous cell carcinoma (HNSCC). Methods and materials: Between 1992 and 2005 127 patients (median age 55 years, UICC stage III n = 6, stage IV n = 121) with primarily inoperable, advanced HNSCC were treated with definite platinum-based radiochemotherapy (median dose 66.4 Gy). Analysed end-points were overall survival (OS), disease-free survival (DFS), loco-regional progression-free survival (LPFS), development of distant metastases (DM), prognostic factors and causes of death. Results: The mean follow-up time was 34 months (range, 3-156 months), the 3-, 5- and 10-year OS rates were 39%, 28% and 14%, respectively. The median OS was 23 months. Forty-seven patients achieved a complete remission and 78 patients a partial remission. The median LPFS was 17 months, the 3-, 5- and 10-year LPFS rates were 41%, 33% and 30%, respectively. The LPFS was dependent on the nodal stage (p = 0.029). The median DFS was 11 months (range, 2-156 months), the 3-, 5- and 10-year DFS rates were 30%, 24% and 22%, respectively. Prognostic factors in univariate analyses were alcohol abuse (n = 102, p = 0.015), complete remission (n = 47, p < 0.001), local recurrence (n = 71, p < 0.001), development of DM (n = 45, p < 0.001; median OS 16 months) and borderline significance in nodal stage N2 versus N3 (p = 0.06). Median OS was 26 months with lung metastases (n = 17). Nodal stage was a predictive factor for the development of DM (p = 0.025). Cause of death was most commonly tumor progression. Conclusions: In stage IV HNSCC long-term survival is rare and DM is a significant predictor for mortality. If patients developed DM, lung metastases had the most favourable prognosis, so intensified palliative treatment might be justified in DM limited to the lungs.
引用
收藏
页数:7
相关论文
共 33 条
[1]   Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution [J].
Adelstein, DJ ;
Saxton, JP ;
Rybicki, LA ;
Esclamado, RM ;
Wood, BG ;
Strome, M ;
Lavertu, P ;
Lorenz, RR ;
Carroll, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1064-1071
[2]  
Alvi A, 1997, HEAD NECK-J SCI SPEC, V19, P500, DOI 10.1002/(SICI)1097-0347(199709)19:6<500::AID-HED7>3.0.CO
[3]  
2-2
[4]   Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[5]  
BATZLER W, 2008, KREBS DTSCH 2003 200
[6]   Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].
Bernier, J ;
Domenge, C ;
Ozsahin, M ;
Matuszewska, K ;
Lefèbvre, JL ;
Greiner, RH ;
Giralt, J ;
Maingon, P ;
Rolland, F ;
Bolla, M ;
Cognetti, F ;
Bourhis, J ;
Kirkpatrick, A ;
van Glabbeke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952
[7]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[8]   Hyperfractionated or accelerated radiotherapy in head and neck cancer:: a meta-analysis [J].
Bourhis, Jean ;
Overgaard, Jens ;
Audry, Helene ;
Ang, Kian K. ;
Saunders, Michele ;
Bernier, Jacques ;
Horiot, Jean-Claude ;
Le Maitre, Aurlie ;
Pajak, Thomas F. ;
Paulsen, Michael G. ;
O'Sullivan, Brian ;
Dobrowsky, Werner ;
Hliniak, Andrzej ;
Skladowski, Krzysztof ;
Hay, John H. ;
Pinto, Luiz H. J. ;
Fallai, Carlo ;
Fu, Karen K. ;
Sylvester, Richard ;
Pignon, Jean-Pierre .
LANCET, 2006, 368 (9538) :843-854
[9]   Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience [J].
Brockstein, B ;
Haraf, DJ ;
Rademaker, AW ;
Kies, MS ;
Stenson, KM ;
Rosen, F ;
Mittal, BB ;
Pelzer, H ;
Fung, BB ;
Witt, ME ;
Wenig, B ;
Portugal, L ;
Weichselbaum, RW ;
Vokes, EE .
ANNALS OF ONCOLOGY, 2004, 15 (08) :1179-1186
[10]   Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma [J].
Denis, F ;
Garaud, P ;
Bardet, E ;
Alfonsi, M ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Calais, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :69-76